Which Factors Will Push The Generic Central Nervous System Drugs Market To Achieve $123.41 Billion By 2029?
Claim 20% Off Global Market Reports With Code ONLINE20 – Insights on Tariff Effects, Global Trade, and Industry Disruptors
What Are The Future Growth Projections For The Generic Central Nervous System Drugs Market Size?
In recent times, there has been substantial growth in the market size of generic central nervous system drugs. The market, which was valued at $88.43 billion in 2024, is projected to grow to $93.53 billion in 2025. This represents a compound annual growth rate (CAGR) of 5.8%. Several factors have contributed to the growth observed in the historic period. These include an increased number of surgeries, robust growth in emerging markets, escalated pharmaceutical research and development activities, the aging population, and greater healthcare spending.
The market size for generic drugs related to the central nervous system is projected to witness robust expansion in the upcoming years, escalating to “$123.41 billion in 2029 at a compound annual growth rate (CAGR) of 7.2%. The projected growth during the forecast period can be crediting to increasing governmental efforts toward mental health awareness, a surge in healthcare spending, a growing elderly population, and an impressive line-up of drugs under development. During the forecast period, significant trends include investment in wearable tech, the integration of biomarkers in CNS development, the modification of currently available drugs, investment in drug pipelines, the utilization of 3D printing for drug production, and an emphasis on developing partnerships with established companies and research institutions.
Get A Free Sample Of The Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=9315&type=smp
Which Key Factors Are Fueling Growth In The Generic Central Nervous System Drugs Market?
The surge in mental health disorders is anticipated to drive the expansion of the generic central nervous system (CNS) drug market. A mental health disorder, characterized by significant disturbances in a person’s cognitive, emotional, or behavioral functioning, usually causes distress or affects critical functional areas. Generic CNS drugs serve an indispensable role in managing mental health disorders by making treatment options more affordable and accessible. As per the Health and Social Care Information Centre, a UK-based federal authority that gives content, data, and computer systems for professionals, doctors, and decision-makers in the health and social care sectors, in November 2022, there was a rise in the percentage of 17- to 19-year-olds with a probable mental disorder. It increased from 17.4% in 2021 to 25.7% in 2022. Hence, the escalating prevalence of mental health disorders is propelling the growth of the generic CNS drug market.
What Is The Segment Breakdown Of The Generic Central Nervous System Drugs Market?
The generic central nervous system drugs market covered in this report is segmented –
1) By Type: Multiple Sclerosis (MS), Anti-Psychotic, Analgesics, Anti-Parkinson Drugs, Anesthetics, Anti-Epileptics, Anti-Depressants, Other Types
2) By Drug Classification: Branded Drugs, Generic Drugs
3) By Disease: Neurovascular Diseases, CNS Trauma, Mental Health, Neurodegenerative Diseases, Infectious Diseases, CNS Cancer
4) By Route Of Administration: Oral, Intravenous, Intranasal Or Inhalation, Other Route Of Administrations
5) By Mode Of Purchase: Over-The-counter drugs, Prescription-Based Drugs
6) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels
Subsegments:
1) By Multiple Sclerosis (MS): Interferons, Glatiramer Acetate, Sphingosine-1 Phosphate Receptor Modulators, Monoclonal Antibodies
2) By Anti-Psychotic: Atypical Antipsychotics, Typical Antipsychotics
3) By Analgesics: Non-Opioid Analgesics, Opioid Analgesics, Combination Analgesics
4) By Anti-Parkinson Drugs: Dopamine Agonists, MAO-B Inhibitors, COMT Inhibitors, Anticholinergics
5) By Anesthetics: General Anesthetics, Local Anesthetics
6) By Anti-Epileptics: Sodium Channel Blockers, GABA Enhancers, Glutamate Modulators, Other Mechanisms
7) By Anti-Depressants: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs), Tricyclic Antidepressants (TCAs), Monoamine Oxidase Inhibitors (MAOIs), Atypical Antidepressants
8) By Other Types: Cognitive Enhancers, Anxiolytics, Sleep Aids
How Are Global Trends Impacting The Development Of The Generic Central Nervous System Drugs Market?
The focus of key players in the generic central nervous system drugs market is on the creation of biosimilars for ailments related to the central nervous system (CNS). The emerging trend is the production and sanction of biosimilars for specific biologic drugs employed in managing CNS complications, which present a more economically viable alternative to branded biologics. For example, natalizumab-sztn, the premier biosimilar for the treatment of relapsing versions of multiple sclerosis (MS), was launched by Swiss pharmaceutical firm Sandoz in October 2023. The types of MS it tackles include clinically isolated syndrome, relapsing-remitting MS, and active secondary progressive MS. MS is a chronic, progressive auto-immune disorder impacting the CNS. Most individuals affected by this disease experience periods of relapse and remission, severely affecting their life quality. However, this treatment is not recommended for patients diagnosed with progressive multifocal leukoencephalopathy (PML) or those with a history of the condition.
Which Firms Are Driving Innovation Within The Generic Central Nervous System Drugs Market?
Major companies operating in the generic central nervous system drugs market include Biogen Inc., Johnson & Johnson, Hoffmann-La Roche Ltd, Novartis AG, UCB, Sanofi, Pfizer Inc., Merck KGaA, Sumitomo Dainippon Pharma, AbbVie, Recipharm AB, Neuraxpharm, Sun Pharmaceutical limited, Ranbaxy Laboratories, Merz Pharma GmbH & Co. KGaAare, AstraZeneca, Apotex, Gilead Sciences, Bayer, GlaxoSmithKline, Amgen, Abbott Laboratories, Janssen Pharmaceutica, Teva Canada, Accord Healthcare Inc., Acerus Pharmaceuticals Corporation, Amgen, EMS Pharma, Hypermarcas, Eurofarma, Teuto Brasileiro, Biolab Farmaceutica, Cristalia, União Quimica, Boehringer Ingelheim, Eli Lilly and Company, Adcock Ingram
Access The Complete Report Here:
Which Region Is Likely To Register The Fastest Growth In The Generic Central Nervous System Drugs Market?
North America was the largest region in the generic central nervous system drugs market in 2024. The regions covered in the generic central nervous system drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Customize Your Report Here:
https://www.thebusinessresearchcompany.com/customise?id=9315&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
